➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Baxter
Moodys

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FERUMOXYTOL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Ferumoxytol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00087347 ↗ Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer Completed National Cancer Institute (NCI) N/A 2004-09-01 RATIONALE: Diagnostic procedures such as magnetic resonance imaging (MRI) using ferumoxytol may improve the ability to detect cancer that has spread to the lymph nodes and may help plan effective cancer treatment. PURPOSE: This clinical trial is studying how well MRI using ferumoxytol works in detecting metastases to the lymph nodes in patients with primary prostate cancer or primary breast cancer.
NCT00087347 ↗ Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer Completed Massachusetts General Hospital N/A 2004-09-01 RATIONALE: Diagnostic procedures such as magnetic resonance imaging (MRI) using ferumoxytol may improve the ability to detect cancer that has spread to the lymph nodes and may help plan effective cancer treatment. PURPOSE: This clinical trial is studying how well MRI using ferumoxytol works in detecting metastases to the lymph nodes in patients with primary prostate cancer or primary breast cancer.
NCT00103038 ↗ Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases Active, not recruiting National Cancer Institute (NCI) N/A 2004-02-01 This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer that has spread to the brain. Diagnostic procedures, such as MRI, may help find and diagnose brain tumors and find out how far the disease has spread. The contrast imaging agent ferumoxytol non-stoichiometric magnetite consists of small iron particles taken by the blood stream to the brain and to the area of the tumor. It may help visualize the blood flow going through the tumor better than the standard substance gadolinium-based contrast agent.
NCT00103038 ↗ Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases Active, not recruiting OHSU Knight Cancer Institute N/A 2004-02-01 This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer that has spread to the brain. Diagnostic procedures, such as MRI, may help find and diagnose brain tumors and find out how far the disease has spread. The contrast imaging agent ferumoxytol non-stoichiometric magnetite consists of small iron particles taken by the blood stream to the brain and to the area of the tumor. It may help visualize the blood flow going through the tumor better than the standard substance gadolinium-based contrast agent.
NCT00233597 ↗ Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients Completed AMAG Pharmaceuticals, Inc. Phase 3 2004-08-01 The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients on hemodialysis.
NCT00255424 ↗ Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients Completed AMAG Pharmaceuticals, Inc. Phase 3 2004-05-01 The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients with chronic kidney disease who are not on dialysis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ferumoxytol

Condition Name

Condition Name for Ferumoxytol
Intervention Trials
Iron Deficiency Anemia 12
Anemia 7
Childhood Brain Neoplasm 3
Prostate Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ferumoxytol
Intervention Trials
Anemia, Iron-Deficiency 21
Anemia 21
Deficiency Diseases 14
Renal Insufficiency, Chronic 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ferumoxytol

Trials by Country

Trials by Country for Ferumoxytol
Location Trials
United States 148
Canada 2
United Kingdom 1
Netherlands 1
Russian Federation 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ferumoxytol
Location Trials
Massachusetts 20
Oregon 15
California 13
Maryland 11
Pennsylvania 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ferumoxytol

Clinical Trial Phase

Clinical Trial Phase for Ferumoxytol
Clinical Trial Phase Trials
Phase 4 9
Phase 3 15
Phase 2/Phase 3 1
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ferumoxytol
Clinical Trial Phase Trials
Recruiting 19
Completed 17
Not yet recruiting 15
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ferumoxytol

Sponsor Name

Sponsor Name for Ferumoxytol
Sponsor Trials
AMAG Pharmaceuticals, Inc. 26
National Cancer Institute (NCI) 20
OHSU Knight Cancer Institute 12
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ferumoxytol
Sponsor Trials
Other 60
Industry 31
NIH 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Baxter
Dow
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.